The evolving treatment of dry eye

Ophthalmology Clinics of North America

Volumn 16, Issue 1, 2003, Pages 29-35

  Foulks, Gary N ^a  

^a University of Pittsburgh School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIHISTAMINIC AGENT; ARTIFICIAL TEAR; BROMHEXINE; BROMHEXINE DERIVATIVE; CEVIMELINE; CYCLOSPORIN; CYCLOSPORIN A; DIAZEPAM; DIQUAFOSOL; ESTROGEN; GAMMA LINOLENIC ACID; HYDROEYE; LUBRICATING AGENT; OMEGA 6 FATTY ACID; PILOCARPINE; PRIMROSE OIL; PURINE P2Y2 RECEPTOR STIMULATING AGENT; PURINERGIC RECEPTOR STIMULATING AGENT; REFRESH ENDURA; TESTOSTERONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

ANAPHYLAXIS; AUTOLOGOUS SERUM THERAPY; BLOOD AUTOTRANSFUSION; CLINICAL TRIAL; DIARRHEA; DRUG FATALITY; DRUG MECHANISM; DRUG USE; DRY EYE; EYE INJURY; EYE IRRITATION; EYE SURFACE; HOMEOSTASIS; HORMONAL REGULATION; HUMAN; IMMUNOMODULATION; INFLAMMATION; KERATOCONJUNCTIVITIS SICCA; LACRIMAL DUCT OCCLUSION; LACRIMAL FLUID; LACRIMAL GLAND; LACRIMAL GLAND DISEASE; PALLIATIVE THERAPY; PRIORITY JOURNAL; REVIEW; SERUM; SURGICAL TECHNIQUE; SWEAT GLAND DISEASE; TEAR FILM;

DRY EYE SYNDROMES; HUMANS; TEARS;

EID: 0037352519     PISSN: 08961549     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0896-1549(02)00105-0     Document Type: Review

References (51)

1. Mathers WD. Why the eye becomes dry: a cornea and lacrimal gland feedback model. CLAO J 2000;26:159-65.
2. Pflugfelder SC, Solomon A, Stern ME. The diagnosis and management of dry eye: 25 year review. Cornea 2000;19:644-9.
3. Gougerot H. Insufficiance progressive et atrophie des glandes salivaires et musqueuses de la bouche, des conjunctives (et parfois des muqueuses nasale, laryngee, vulvaire). Bull Soc Fran Derm Syph 1925;32:376-9.
4. Sjogren HSC. Zur kenntnis der keratoconjunctivitis sicca (Keratitis filiformis bei Hypofunktion der Tranendrusen. Acta Ophthalmologica (Kbh) 1933;Supp 2:1-151.
5. th ed. New York: Blackstone; 1954. p. 20-34.
6. Holly FJ, Lemp MA. Tear physiology and dry eyes. Surv Ophthalmol 1977;22:69-87.
7. Dilly PN. Structure and function of the tear film. Adv Exp Med Biol 1994;350:239-47.
8. McCulley JP, Shine W. A compositional based model for the tear film lipid layer. Trans Am Ophthalmol Soc 1997;95:79-88.
9. McCulley JP, Shine WE. Changing concepts in the diagnosis and management of blepharitis. Cornea 2000;19:650-8.
10. Shine WE, McCulley JP. Keratoconjunctivitis sicca associated with meibomian secretion polar lipid abnormality. Arch Ophthalmol 1998;116:849-52.
11. Rolando M, Zierhut M. The ocular surface and tear film and their dysfunction in dry eye disease. Surv Ophthalmol 2001;45(suppl 2):S203-10.
12. Gilbard JP. Dry eye disorders. In: Albert DM, Jakobiec FA, editors. Principles and Practice of Ophthalmology-Clinical Practice. Philadelphia: WB Saunders; 1994. p. 257-76.
13. Gilbard JP, Carter JB, Sang DN, et al. Morphologic effect of hyperosmolarity on rabbit comeal epithelium. Ophthalmology 1984;91:1205-12.
14. Stern ME, Beuerman RW, Fox RI, Gao J, Mircheff AK, Pflugfelder SC. The pathology of dry eye: the interaction between the ocular surface and the lacrimal glands. Cornea 1998;17:584-9.
15. Sullivan DA, Krenzer KL, Sullivan BD, et al. Does androgen insufficiency cause lacrimal gland inflammation and aqueous tear deficiency? Invest Ophthalmol Vis Sci 1999;40:1261-5.
16. Suzuki T, Schaumberg DA, Sullivan BD, Liu M, Richards SM, Sullivan RM, et al. Do estrogen and progesterone play a role in the dry eye of Sjogren syndrome. Ann N Y Acad Sci 2002;966:223-5.
17. Foulks GN. The now and future therapy of non-Sjogrens dry eye. Adv Exp Med Biol 1998;438:959-64.
18. Tsubota K, Nakamori K. Dry eyes and video display terminals. N Engl J Med 1993;328:584.
19. Lemp MA. Report of the National Eye Institute/Industry Workshop on Clinical Trials in Dry Eye. CLAO J 1995;21:221-32.
20. Mathers WD, Lane JA. Meibomian gland lipids, evaporation, and tear film stability. Adv Exp Med Biol 1998;438:349-60.
21. Mathers WD. Ocular evaporation in meibomian gland dysfunction and dry eye. Ophthalmology 1993;100: 347-51.
22. Foulks GN. Management of meibomian glands disease. In: Tiffany J, editor. The meibomian glands: secretion, pathology and contact lens problems. Lisse, The Netherlands: Swets & Zeitlinger Publishers; 2003.
23. Dougherty JM, McCulley JP, Silvany RE, Meyers DR. The role of tetracycline in chronic blepharitis: inhibition of lipase production in staphylococci. Invest Ophthalmol Vis Sci 1991;32:2970-5.
24. Calonge M. The treatment of dry eye. Surv Ophthalmol 2001;45(suppl 2):S227-39.
25. Murube J, Paterson A, Murube E. Classification of artificial tears, I: composition and properties. Adv Exp Med Biol 1998;438:693-704.
26. Murube J, Murube A, Zhuo C. Classification of artificial tears, II: additives and commercial formulas. Adv Exp Med Biol 1998;438:705-15.
27. Gilbard JP. Human tar film electrolyte concentrations in health and dry-eye disease. Int Ophthalmol Clin 1994;34:27-36.
28. Gilbard JP, Rossi SR. An electrolyte-based solution that increases comeal glycogen and conjunctival goblet cell density in a rabbit model for keratoconjunctivitis sicca. Ophthalmology 1992;99:600-4.
29. Holly FJ, Lamberts DW. Effect of nonisotonic solutions on tear film osmolality. Invest Ophthalmol Vis Sci 1981;20:236-45.
30. Tsubota K. New approaches to dry eye therapy. Int Ophthalmol Clin 1994;34:115-28.
31. Tsubota K, Yamada M, Uruyama K. Spectacle side shield panels and moisture sponge for treatment of dry eye patients. Cornea 1994;13:192-201.
32. Murube J, Murube E. Treatment of dry eye by blocking the lacrimal canaliculi. Surv Ophthalmol 1996;40: 463-80.
33. Balaram M, Schaumberg DA, Dana MR. Efficacy and tolerability outcomes after punctal occlusion with silicone plugs in dry eye syndrome. Am J Ophthalmol 2001;131:30-6.
34. Will DV, McNally LM, Roth RE. Pyogenic granuloma complicating Parasoltm (Odyssey™) silicone punctal plug occlusion: a series review. Invest Ophthalmol Vis Sci 2000;41:S69.
35. Yen MT, Monroy D, Pflugfelder SC. Punctal occlusion decreases tear production, clearance, and ocular surface sensation. Invest Ophthalmol Vis Sci 1999; 40:S980.
36. Nelson JD, Friedlander M, Yeatts RP, Yee R, et al. Oral pilocarpine for symptomatic relief of keratoconjunctivitis sicca in patients with Sjogren syndrome: the MGI Pharma Sjogren syndrome study group. Adv Exp Med Biol 1998;438:979-83.
37. Mathers WD, Dolney AM. Objective demonstration of tear stimulation with oral pilocarpine in dry eye patients. Invest Ophthamol Vis Sci 2000;41:S60.
38. Petrone D, Condemi JJ, Fife R, Gluck O, Cohen S, Dalgin P. A double-blind, randomized, placebo-controlled study of cevimeline in Sjogren syndrome patients with xerostomia and keratoconjunctivitis sicca. Arthritis Rheum 2002;46:748-54.
39. Gilbard JP, Rossi SR, Heyda KG, Dartt DA. Stimulation of tear secretion by topical agents that increase cyclic nucleotide levels. Invest Ophthalmol Vis Sci 1990; 31:1381-8.
40. Li Y, Kuang K, Yerxa B, Wen Q, Rosskothen H, Fischbarg J. Rabbit conjunctival epithelium transports fluid, and P2Y2 (2) receptor agonists stimulate Cl(-) and fluid secretion. Am J Physiol Cell Phys 2001;281: C595-602.
41. Foulks G, Sall K, Greenberg M, et al. Phase 2 dose ranging efficacy trial of INS365 ophthalmic solution, a P2Y2 agonist, in patients with dry eye. ARVO Abstracts. Invest Ophthalmol Vis Sci 2001;42:S713.
42. Marsh P, Pflugfelder SC. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjogren syndrome. Ophthalmology 1999;106:811-6.
43. Kunert KS, Tisdale AS, Stern ME, Smith JA, Gipson IK. Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. Arch Ophthalmol 2000;118: 1489-96.
44. Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease: CsA Phase III Study Group. Ophthalmology 2000;107:631-9.
45. Stevenson D, Tauber J, Reis BL, et al. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate -to-severe dry eye disease: a dose-ranging randomized trial. Ophthalmology 2000;107:967-74.
46. Sullivan DA, Wickham LA, Rocha EM, et al. Androgens and dry eye in Sjogren syndrome. Ann N Y Acad Sci 1999;876:312-24.
47. Schaumberg DA, Buring JE, Sullivan DA, Dana MR. Hormone replacement therapy and dry eye syndrome. JAMA 2001;286:2114-9.
48. Horrobin DF. Essential fatty acid and prostaglandin metabolism in Sjogren syndrome, systemic sclerosis, and rheumatoid arthritis. Scand J Rheumatol 1986; 61(suppl):242-5.
49. Fox RI, Chan R, Michelson JB, Belmont JB, Michelson PE. Beneficial effect of artificial tears made with autologous serum in patients with keratoconjunctivitis sicca. Arthritis Rheum 1984;27:459-61.
50. Tsubota K, Goto E, Fujita H, Ono M, Inoue H, Saito I, et al. Treatment of dry eye by autologous serum application in Sjogren syndrome. Br J Ophthalmol 1999;83: 390-5.
51. Tsubota K, Higuchi A. Serum application for treatment of ocular surface disease. Int Ophthalmol Clin 2000; 40:113-22.